Article Figures & Data
Figures
- FIGURE 1.
Chemical structure of novel melanin-binding benzamide 131I-BA52.
- FIGURE 2.
(A) Biodistribution of 131I-BA52 in patient with malignant melanoma. Arrows indicate uptake of benzamide in melanin-bearing cells of eyes, specific uptake in tumor lesions (auxiliary) as identified by 18F-FDG (B), unspecific uptake in lungs, and elimination through liver and bowel.
- FIGURE 3.
(A) A 68-y-old patient with liver and bone (sternum) metastases of malignant melanoma. Tumor lesions were identified by 18F-FDG PET. Tumor residence time and elimination pathway were determined with scans of 123I-BA52 at 4 h (B) to 24 h (C) after injection. Side-by-side reading with 18F-FDG demonstrates highly specific accumulation and also long retention time in tumor tissue. Increasing contrast of bowel corresponds to hepatoenteral excretion.
- FIGURE 4.
A 59-y-old patient with malignant melanoma of left lower extremity causing lymph node metastasis inguinal and paraortal up to mediastinum. 18F-FDG PET maximum-intensity projection (A) demonstrates metastases inguinal and paraaortal, both abdominal and mediastinal. One example of paraaortal metastasis (B) presented with intense 18F-FDG accumulation (standardized uptake value [SUV], 12.3) in pretherapeutic PET/CT that changed to 18F-FDG–negative in follow-up PET/CT 6 wk after therapy (C). Inguinal lymph node metastasis with initially intense 18F-FDG-uptake (D) (SUV, 9.02) decreased in size and metabolism (SUV, 5.81) in posttherapy 18F-FDG PET/CT (E).
Tables
- TABLE 1
Summary of Dosimetric Gy/GBq Values of 131I-BA52 Estimated for Organs and Tumor Lesions
Organ Dose (Gy/GBq) Adrenals 0.35 Brain 0.19 Breasts 0.24 Gallbladder wall 0.43 Lower large intestine wall 3.10 Small intestine 0.39 Stomach wall 0.30 Upper large intestine wall 4.64 Heart wall 0.36 Kidneys 0.30 Liver 1.30 Lungs 3.15 Muscle 0.25 Ovaries 0.36 Pancreas 0.34 Red marrow 0.20 Osteogenic cells 0.40 Skin 0.19 Spleen 0.59 Testes 0.19 Thymus 0.29 Thyroid 0.23 Urinary bladder wall 0.66 Uterus 0.30 Total body 0.33 Effective dose equivalent 0.99 Effective dose 0.92 Eyes Ciliary body 5.7–15.4 Choroid 8.1 Retina 2.7 Melanoma metastases Mean ± SD 5.5 ± 3.6 Range 1.13–12.2
Supplemental Data
Files in this Data Supplement:
Jump to section
Related Articles
Cited By...
- Melanin-Targeting Radiotracers and Their Preclinical, Translational, and Clinical Status: From Past to Future
- Identification of Ligands and Translation to Clinical Applications
- Approaches to Improve the Pharmacokinetics of Radiolabeled Glucagon-Like Peptide-1 Receptor Ligands Using Antagonistic Tracers
- Whither Goest Thou, Radiopharmaceutical Therapy?